158 related articles for article (PubMed ID: 31481667)
1. Nb-induced stabilisation of p53 in HPV-infected cells.
Steels A; Vannevel L; Zwaenepoel O; Gettemans J
Sci Rep; 2019 Sep; 9(1):12680. PubMed ID: 31481667
[TBL] [Abstract][Full Text] [Related]
2. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
3. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
4. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation.
Razani B; Altschuler Y; Zhu L; Pestell RG; Mostov KE; Lisanti MP
Biochemistry; 2000 Nov; 39(45):13916-24. PubMed ID: 11076533
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: role of p53, ICE-like proteases and the mitochondrial permeability transition.
Brown J; Higo H; McKalip A; Herman B
J Cell Biochem; 1997 Aug; 66(2):245-55. PubMed ID: 9213225
[TBL] [Abstract][Full Text] [Related]
6. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
7. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
8. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
[TBL] [Abstract][Full Text] [Related]
9. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
10. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells.
Beer-Romero P; Glass S; Rolfe M
Oncogene; 1997 Feb; 14(5):595-602. PubMed ID: 9053858
[TBL] [Abstract][Full Text] [Related]
11. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines.
Liang XH; Volkmann M; Klein R; Herman B; Lockett SJ
Oncogene; 1993 Oct; 8(10):2645-52. PubMed ID: 8397367
[TBL] [Abstract][Full Text] [Related]
12. HMGB2 stabilizes p53 by interfering with E6/E6AP-mediated p53 degradation in human papillomavirus-positive HeLa cells.
Lee D; Kwon JH; Kim EH; Kim ES; Choi KY
Cancer Lett; 2010 Jun; 292(1):125-32. PubMed ID: 20036050
[TBL] [Abstract][Full Text] [Related]
13. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
Zimmermann H; Degenkolbe R; Bernard HU; O'Connor MJ
J Virol; 1999 Aug; 73(8):6209-19. PubMed ID: 10400710
[TBL] [Abstract][Full Text] [Related]
14. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
Münger K; Scheffner M; Huibregtse JM; Howley PM
Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
[TBL] [Abstract][Full Text] [Related]
15. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
16. Neocarzinostatin induces an effective p53-dependent response in human papillomavirus-positive cervical cancer cells.
Bañuelos A; Reyes E; Ocadiz R; Alvarez E; Moreno M; Monroy A; Gariglio P
J Pharmacol Exp Ther; 2003 Aug; 306(2):671-80. PubMed ID: 12750435
[TBL] [Abstract][Full Text] [Related]
17. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
Tomaić V; Pim D; Banks L
Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits viral oncogene expression leading to apoptosis and inhibition of cervical cancer.
Munagala R; Aqil F; Jeyabalan J; Gupta RC
Cancer Lett; 2015 Jan; 356(2 Pt B):536-46. PubMed ID: 25304375
[TBL] [Abstract][Full Text] [Related]
19. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
20. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]